Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Johnson & Johnson (JNJ)
USD257.77
+0.79 (+0.31%)
US NYSE DJIA
S&P 500
Healthcare Drug Manufacturers - General
Address
One Johnson & Johnson Plaza 8933
New Brunswick, NJ, US
New Brunswick, NJ, US
CEO
Joaquin Duato
Website
jnj.com
IPO
1962-01-02
CIK 200406 ISIN US4781601046
Also trades on
Deutsche Börse · JNJ.DE (EUR)
New York Stock Exchange · JNJ (USD)
Swiss Exchange · JNJ.SW (CHF)
Description
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
News Sentiment (7d)
9 articles
- How To Build A $50,000 Dividend Portfolio In Today's Market Seeking Alpha
- The Dividend Growth Roadmap That Turns $60,000 a Year Into More Than $125,000 247 Wallst
- Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release? Zacks Investment Research
- JNJ Vs. KO: Which Dividend Stock Is The Better Buy? 24/7 Wall Street
- Stock Indexes Split as Chip Stocks Fall, Oil Surges Fool - Investing News
Market Cap & Enterprise Value
Merger & Acquisition History
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| DJIA | 1997-03-17 | — | Active |
| S&P 500 | 1973-05-31 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD257.77
+0.79 (+0.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.26
Float Shares
2.40B
Free Float %
99.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.37% | -3.29% | -1.97% | -9.30% | +8.90% | +8.88% | +45.18% | +45.97% | +36.13% | +99.96% | +18,369.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (40 ratings, all time)
Buy
Price Targets & DCF
Current price
257.77
Low
208.00
-19.3%
Consensus
250.58
-2.8%
Median
252.50
-2.0%
High
283.00
+9.8%
DCF (Unlevered)
334.41
+29.7%
DCF (Levered)
293.76
+14.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
58% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 10 | +1 |
| Hold | 10 | 0 |
| Sell | 0 | -1 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
265.00
+2.8%
|
| Last Quarter | 8 |
263.00
+2.0%
|
| Last Year | 37 |
228.57
-11.3%
|
| All Time | 83 |
199.43
-22.6%
|
Quality scores
Altman Z-Score
4.88
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Drug Manufacturers - General: +6.6%+6.1% Q1'26: +9.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+90.5% ★ Q1'26: -52.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+17.8% Q1'26: +6.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+35.6% ★ Q1'26: +26.6% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+25.2% ★ Q1'26: +29.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.17× Q1'26: 0.68× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 1997 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2008 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 14 EPS Ana. |
Dec 2027 18 Rev. Ana. 14 EPS Ana. |
Dec 2028 17 Rev. Ana. 5 EPS Ana. |
Dec 2029 11 Rev. Ana. 2 EPS Ana. |
Dec 2030 15 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
22.63B
est: 23.07B (-1.9%)
|
36.30B
est: 36.37B (-0.2%)
|
41.86B
est: 41.21B (+1.6%)
|
63.75B
est: 61.00B (+4.5%)
|
71.31B
est: 68.63B (+3.9%)
|
74.33B
est: 71.43B (+4.1%)
|
70.07B
est: 70.11B (-0.1%)
|
71.89B
est: 72.02B (-0.2%)
|
76.45B
est: 76.26B (+0.2%)
|
81.58B
est: 81.40B (+0.2%)
|
82.06B
est: 82.13B (-0.1%)
|
81.80B
est.
|
82.58B
est: 94.45B (-12.6%)
|
78.74B
est: 95.02B (-17.1%)
|
85.16B
est: 86.58B (-1.6%)
|
79.99B
est: 86.58B (-7.6%)
|
88.82B
est: 88.78B (+0.0%)
|
94.19B
est: 93.76B (+0.5%)
|
100.91B
100.72B – 101.17B
+7.6% YoY
|
107.75B
104.62B – 109.37B
+6.8% YoY
|
114.99B
114.91B – 115.07B
+6.7% YoY
|
121.70B
118.41B – 123.70B
+5.8% YoY
|
131.81B
128.25B – 133.97B
+8.3% YoY
|
| EBITDA |
5.69B
est: 5.38B (+5.8%)
|
11.34B
est: 10.95B (+3.6%)
|
12.74B
est: 11.99B (+6.3%)
|
20.20B
est: 18.85B (+7.1%)
|
20.06B
est: 19.24B (+4.2%)
|
24.99B
est: 23.92B (+4.5%)
|
23.49B
est: 21.24B (+10.6%)
|
24.28B
est: 21.82B (+11.3%)
|
24.25B
est: 23.11B (+4.9%)
|
25.93B
est: 24.66B (+5.1%)
|
24.66B
est: 23.82B (+3.5%)
|
24.62B
est.
|
23.93B
est: 27.08B (-11.6%)
|
26.75B
est: 29.79B (-10.2%)
|
23.32B
est: 28.76B (-18.9%)
|
26.61B
est: 28.76B (-7.5%)
|
24.78B
est: 29.49B (-16.0%)
|
41.06B
est: 31.15B (+31.8%)
|
33.52B
33.46B – 33.61B
+7.6% YoY
|
35.79B
34.76B – 36.33B
+6.8% YoY
|
38.20B
38.17B – 38.23B
+6.7% YoY
|
40.43B
39.34B – 41.09B
+5.8% YoY
|
43.79B
42.60B – 44.51B
+8.3% YoY
|
| EBIT |
4.62B
est: 4.59B (+0.8%)
|
9.68B
est: 9.67B (+0.0%)
|
10.87B
est: 10.70B (+1.6%)
|
17.36B
est: 15.41B (+12.6%)
|
15.95B
est: 18.20B (-12.4%)
|
21.10B
est: 20.23B (+4.3%)
|
19.75B
est: 15.09B (+30.9%)
|
20.53B
est: 15.50B (+32.5%)
|
18.61B
est: 16.41B (+13.4%)
|
19.00B
est: 17.51B (+8.5%)
|
17.65B
est: 20.20B (-12.7%)
|
18.51B
est.
|
16.70B
est: 20.36B (-18.0%)
|
19.36B
est: 22.39B (-13.5%)
|
15.83B
est: 21.30B (-25.6%)
|
19.64B
est: 21.30B (-7.8%)
|
17.44B
est: 21.84B (-20.1%)
|
33.55B
est: 23.06B (+45.5%)
|
24.82B
24.77B – 24.89B
+7.6% YoY
|
26.50B
25.73B – 26.90B
+6.8% YoY
|
28.28B
28.26B – 28.30B
+6.7% YoY
|
29.93B
29.12B – 30.43B
+5.8% YoY
|
32.42B
31.54B – 32.95B
+8.3% YoY
|
| Net Income |
3.30B
est: 3.01B (+9.8%)
|
6.60B
est: 6.60B (+0.0%)
|
7.20B
est: 7.09B (+1.6%)
|
12.95B
est: 12.35B (+4.8%)
|
13.83B
est: 13.28B (+4.2%)
|
16.32B
est: 15.62B (+4.5%)
|
15.41B
est: 15.02B (+2.6%)
|
16.54B
est: 16.29B (+1.5%)
|
1.30B
est: 17.68B (-92.6%)
|
15.30B
est: 19.83B (-22.9%)
|
15.12B
est: 14.62B (+3.4%)
|
15.69B
est.
|
14.71B
est: 17.26B (-14.7%)
|
20.88B
est: 18.98B (+10.0%)
|
35.15B
est: 16.38B (+114.6%)
|
17.94B
est: 16.38B (+9.5%)
|
14.07B
est: 24.28B (-42.1%)
|
26.80B
est: 26.20B (+2.3%)
|
28.28B
27.83B – 28.73B
+8.0% YoY
|
31.48B
29.76B – 33.21B
+11.3% YoY
|
32.58B
26.24B – 38.92B
+3.5% YoY
|
37.81B
36.48B – 38.61B
+16.0% YoY
|
42.46B
40.97B – 43.37B
+12.3% YoY
|
| SGA |
8.72B
est: 8.62B (+1.2%)
|
12.22B
est: 12.24B (-0.2%)
|
14.13B
est: 13.91B (+1.6%)
|
21.49B
est: 20.53B (+4.7%)
|
21.83B
est: 20.97B (+4.1%)
|
21.95B
est: 21.07B (+4.2%)
|
21.20B
est: 17.66B (+20.1%)
|
20.07B
est: 18.14B (+10.6%)
|
21.52B
est: 19.21B (+12.0%)
|
22.54B
est: 20.50B (+9.9%)
|
22.18B
est: 21.43B (+3.5%)
|
20.28B
est.
|
22.08B
est: 22.31B (-1.0%)
|
20.12B
est: 24.54B (-18.0%)
|
20.11B
est: 21.53B (-6.6%)
|
20.25B
est: 21.53B (-6.0%)
|
21.97B
est: 22.08B (-0.5%)
|
23.68B
est: 23.32B (+1.5%)
|
25.10B
25.05B – 25.16B
+7.6% YoY
|
26.80B
26.02B – 27.20B
+6.8% YoY
|
28.60B
28.58B – 28.62B
+6.7% YoY
|
30.27B
29.45B – 30.76B
+5.8% YoY
|
32.78B
31.89B – 33.32B
+8.3% YoY
|
| EPS |
1.24
est: 1.22 (+1.6%)
|
2.20
est: 2.22 (-0.9%)
|
2.42
est: 2.57 (-5.8%)
|
4.67
est: 4.15 (+12.5%)
|
4.90
est: 5.10 (-3.9%)
|
5.86
est: 5.49 (+6.7%)
|
5.57
est: 6.18 (-9.9%)
|
6.08
est: 6.71 (-9.3%)
|
0.48
est: 7.28 (-93.4%)
|
5.75
est: 8.16 (-29.6%)
|
5.74
est: 8.67 (-33.8%)
|
8.00
est.
|
5.59
est: 9.83 (-43.1%)
|
7.93
est: 10.05 (-21.1%)
|
13.88
est: 6.72 (+106.4%)
|
6.83
est: 6.72 (+1.6%)
|
5.84
est: 9.95 (-41.3%)
|
11.03
est: 10.80 (+2.1%)
|
11.58
11.46 – 11.83
+7.2% YoY
|
12.77
12.25 – 13.67
+10.3% YoY
|
14.03
10.80 – 16.02
+9.9% YoY
|
15.56
15.02 – 15.89
+10.9% YoY
|
17.48
16.86 – 17.85
+12.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-13 | Leerink Partners | Market Perform | Outperform | Upgrade |
| 2026-04-15 | Stifel | Hold | Hold | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-01 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
19.43B
OE per share TTM
7.99
Owner's Yield
3.53%
Maintenance CapEx ratio
10.45%
Maint CapEx / Avg PPE
23.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
4,680
Total invested
431.45B
Insider transactions (90d)
12
Beneficial owners (>5%)
8
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group - 23-1945930 | 234.78M | 8.92% | — | 3.96M | 224.34M | 10.44M | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 2 | (1) BlackRock, Inc. | 200.02M | 7.60% | 173.83M | — | 200.02M | — | HC | Delaware | 2022-02-01 | ↗ |
| 3 | STATE STREET CORPORATION | 145.00M | 5.51% | — | 126.28M | — | 144.68M | HC | — | 2022-02-14 | ↗ |
| 4 | EIN: 22-1024240 | 4.11M | 19.60% | — | 4.11M | — | — | CO | New Jersey | 2022-02-07 | ↗ |
| 5 | Johnson & Johnson | 2.50M | 6.80% | — | 2.50M | — | — | CO | New Jersey | 2024-10-18 | ↗ |
| 6 | Johnson & Johnson Innovation-JJDC, Inc. | 2.50M | 6.80% | — | 2.50M | — | — | CO | New Jersey | 2024-10-18 | ↗ |
| 7 | 22-1024240 | 2.13M | 9.30% | — | 2.13M | — | 2.13M | CO | New Jersey | 2019-11-26 | ↗ |
| 8 | EIN: 22-2007137 | 2.13M | 9.30% | — | 2.13M | — | 2.13M | CO | New Jersey | 2019-11-26 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
4,680
+73 vs prev Q
New positions
302
Closed positions
227
Increased
1,995
Reduced
2,128
Put/Call ratio
0.85
Calls held
17.49M
Puts held
14.79M
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 240.35M +3.7M (+1.6%) | 49.74B +5.9B (+13.4%) | 9.90% +0.154 pp | 0.72% +0.064 pp | USD98.97 +109.1% | 84 qtrs — |
| 2 | BLACKROCK, INC. | 208.78M +1.5M (+0.7%) | 43.21B +4.8B (+12.4%) | 8.60% +0.063 pp | 0.73% +0.058 pp | USD162.45 +27.4% | 6 qtrs — |
| 3 | STATE STREET CORP | 133.87M +1.7M (+1.3%) | 27.70B +3.2B (+13.0%) | 5.51% +0.069 pp | 0.93% +0.079 pp | USD100.43 +106.1% | 51 qtrs — |
| 4 | JPMORGAN CHASE & CO | 58.56M -82.6K (-0.1%) | 12.12B +1.2B (+11.5%) | 2.41% -0.003 pp | 0.76% +0.109 pp | USD152.61 +35.6% | 51 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 57.95M +1.7M (+3.1%) | 11.97B +1.6B (+15.2%) | 2.39% +0.072 pp | 0.74% +0.076 pp | USD122.52 +68.9% | 78 qtrs — |
| 6 | MORGAN STANLEY | 46.33M -1.9M (-4.0%) | 9.59B +644.0M (+7.2%) | 1.91% -0.079 pp | 0.57% +0.031 pp | USD145.64 +42.1% | 51 qtrs — |
| 7 | NORGES BANK | 33.46M +33.5M (+100.0%) | 6.92B +6.9B (+100.0%) | 1.38% +1.378 pp | 0.74% +0.741 pp | USD206.95 +0.0% | 1 qtrs NEW |
| 8 | STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 31.59M +— (+0.0%) | 6.54B +680.2M (+11.6%) | 1.30% +0.000 pp | 5.13% +0.251 pp | USD46.84 +341.8% | 108 qtrs — |
| 9 | NORTHERN TRUST CORP | 29.28M -691.1K (-2.3%) | 6.06B +502.3M (+9.0%) | 1.21% -0.029 pp | 0.77% +0.062 pp | USD103.91 +99.2% | 51 qtrs — |
| 10 | BANK OF AMERICA CORP /DE/ | 28.33M -86.2K (-0.3%) | 5.86B +594.0M (+11.3%) | 1.17% -0.004 pp | 0.43% +0.069 pp | USD131.74 +57.1% | 52 qtrs — |
| 11 | BANK OF NEW YORK MELLON CORP | 24.39M -243.4K (-1.0%) | 5.05B +480.1M (+10.5%) | 1.00% -0.010 pp | 0.90% +0.011 pp | USD158.66 +30.4% | 66 qtrs — |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 23.24M -2.6M (-10.0%) | 4.81B +19.3M (+0.4%) | 0.96% -0.107 pp | 0.84% +0.004 pp | USD114.56 +80.6% | 81 qtrs — |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 19.03M +22.2K (+0.1%) | 3.94B +415.4M (+11.8%) | 0.78% +0.001 pp | 0.61% +0.050 pp | USD118.41 +74.8% | 100 qtrs — |
| 14 | FMR LLC | 18.78M +5.3M (+39.7%) | 3.89B +1.4B (+55.9%) | 0.77% +0.220 pp | 0.20% +0.069 pp | USD155.08 +33.4% | 70 qtrs — |
| 15 | LEGAL & GENERAL GROUP PLC | 18.74M -705.5K (-3.6%) | 3.88B +272.8M (+7.6%) | 0.77% -0.029 pp | 0.86% +0.051 pp | USD113.65 +82.1% | 75 qtrs — |
| 16 | WELLS FARGO & COMPANY/MN | 17.85M -607.4K (-3.3%) | 3.69B +271.6M (+7.9%) | 0.73% -0.025 pp | 0.67% +0.022 pp | USD101.22 +104.5% | 57 qtrs — |
| 17 | UBS ASSET MANAGEMENT AMERICAS INC | 17.28M +1.4M (+8.7%) | 3.58B +627.2M (+21.3%) | 0.71% +0.057 pp | 0.76% +0.116 pp | USD139.17 +48.7% | 90 qtrs — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 17.26M -780.8K (-4.3%) | 3.57B +227.2M (+6.8%) | 0.71% -0.032 pp | 0.75% +0.032 pp | USD137.63 +50.4% | 51 qtrs — |
| 19 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 16.39M -1.2M (-6.7%) | 3.39B +135.4M (+4.2%) | 0.67% -0.048 pp | 1.09% +0.085 pp | USD104.68 +97.7% | 51 qtrs — |
| 20 | GOLDMAN SACHS GROUP INC | 16.34M +3.2M (+24.6%) | 3.38B +950.8M (+39.1%) | 0.67% +0.133 pp | 0.41% +0.117 pp | USD158.50 +30.6% | 73 qtrs — |
| 21 | ROYAL BANK OF CANADA | 14.29M +92.6K (+0.7%) | 2.96B +324.8M (+12.3%) | 0.59% +0.004 pp | 0.48% +0.050 pp | USD130.11 +59.1% | 51 qtrs — |
| 22 | DEUTSCHE BANK AG\ | 13.49M -394.5K (-2.8%) | 2.79B +217.4M (+8.4%) | 0.56% -0.016 pp | 0.91% +0.047 pp | USD139.60 +48.2% | 50 qtrs — |
| 23 | AMERIPRISE FINANCIAL INC | 13.45M +272.1K (+2.1%) | 2.78B +339.8M (+13.9%) | 0.55% +0.011 pp | 0.63% +0.068 pp | USD104.34 +98.3% | 55 qtrs — |
| 24 | INVESCO LTD. | 12.73M -888.4K (-6.5%) | 2.63B +109.3M (+4.3%) | 0.52% -0.037 pp | 0.40% +0.006 pp | USD136.78 +51.3% | 57 qtrs — |
| 25 | PRICE T ROWE ASSOCIATES INC /MD/ | 12.42M +3.7M (+41.7%) | 2.57B +945.3M (+58.1%) | 0.51% +0.151 pp | 0.28% +0.103 pp | USD164.34 +25.9% | 75 qtrs — |
| 26 | AMUNDI | 11.41M -1.9M (-14.6%) | 2.36B -152.3M (-6.1%) | 0.47% -0.080 pp | 0.64% -0.166 pp | USD162.74 +27.2% | 19 qtrs — |
| 27 | FRANKLIN RESOURCES INC | 10.80M -5.3M (-33.1%) | 2.23B -758.2M (-25.3%) | 0.44% -0.220 pp | 0.55% -0.198 pp | USD135.01 +53.3% | 51 qtrs — |
| 28 | NUVEEN, LLC | 10.61M +684.0K (+6.9%) | 2.20B +355.2M (+19.3%) | 0.44% +0.028 pp | 0.57% +0.089 pp | USD169.32 +22.2% | 4 qtrs — |
| 29 | RAYMOND JAMES FINANCIAL INC | 10.36M +221.3K (+2.2%) | 2.14B +264.0M (+14.0%) | 0.43% +0.009 pp | 0.67% +0.063 pp | USD149.09 +38.8% | 5 qtrs — |
| 30 | UBS GROUP AG | 9.98M -416.0K (-4.0%) | 2.07B +137.8M (+7.1%) | 0.41% -0.017 pp | 0.34% +0.033 pp | USD141.98 +45.8% | 45 qtrs — |
| 31 | CAPITAL WORLD INVESTORS | 9.69M +9.7M (+100.0%) | 2.01B +2.0B (+100.0%) | 0.40% +0.399 pp | 0.27% +0.273 pp | USD206.95 +0.0% | 1 qtrs NEW |
| 32 | HSBC HOLDINGS PLC | 9.24M -100.5K (-1.1%) | 1.91B +181.7M (+10.5%) | 0.38% -0.004 pp | 0.97% +0.020 pp | USD153.55 +34.8% | 56 qtrs — |
| 33 | FISHER ASSET MANAGEMENT, LLC | 8.87M +419.8K (+5.0%) | 1.83B +268.7M (+17.2%) | 0.37% +0.017 pp | 0.63% +0.059 pp | USD165.40 +25.1% | 57 qtrs — |
| 34 | GQG PARTNERS LLC | 7.75M +1.7M (+28.4%) | 1.60B +484.8M (+43.3%) | 0.32% +0.071 pp | 2.64% +0.922 pp | USD189.98 +8.9% | 7 qtrs — |
| 35 | JANUS HENDERSON GROUP PLC | 7.72M +724.5K (+10.4%) | 1.60B +300.7M (+23.2%) | 0.32% +0.030 pp | 0.72% +0.123 pp | USD161.54 +28.1% | 88 qtrs — |
| 36 | ALLIANCEBERNSTEIN L.P. | 7.70M -237.2K (-3.0%) | 1.59B +121.7M (+8.3%) | 0.32% -0.010 pp | 0.50% +0.040 pp | USD138.45 +49.5% | 61 qtrs — |
| 37 | CAPITAL INTERNATIONAL INVESTORS | 7.47M +3.6M (+93.3%) | 1.55B +829.5M (+115.7%) | 0.31% +0.149 pp | 0.24% +0.127 pp | USD192.91 +7.3% | 39 qtrs — |
| 38 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 7.44M -240.3K (-3.1%) | 1.54B +115.6M (+8.1%) | 0.31% -0.010 pp | 0.88% +0.028 pp | USD114.45 +80.8% | 54 qtrs — |
| 39 | GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC | 7.09M +273.9K (+4.0%) | 1.47B +203.4M (+16.1%) | 0.29% +0.011 pp | 3.75% +0.186 pp | USD143.18 +44.5% | 77 qtrs — |
| 40 | JOURNEY STRATEGIC WEALTH LLC | 7.05M +35.4K (+0.5%) | 1.46B +158.4M (+12.2%) | 0.29% +0.002 pp | 38.36% +1.655 pp | USD165.31 +25.2% | 17 qtrs — |
| 41 | NINETY ONE UK LTD | 6.81M +170.6K (+2.6%) | 1.41B +178.3M (+14.5%) | 0.28% +0.007 pp | 3.02% +0.363 pp | USD140.56 +47.2% | 55 qtrs — |
| 42 | SWISS NATIONAL BANK | 6.60M -336.1K (-4.8%) | 1.37B +79.8M (+6.2%) | 0.27% -0.014 pp | 0.81% +0.067 pp | USD121.82 +69.9% | 51 qtrs — |
| 43 | ALLIANZ ASSET MANAGEMENT GMBH | 6.02M +559.4K (+10.2%) | 1.25B +233.3M (+23.0%) | 0.25% +0.023 pp | 1.26% +0.129 pp | USD148.17 +39.7% | 51 qtrs — |
| 44 | PNC FINANCIAL SERVICES GROUP, INC. | 5.99M -150.0K (-2.4%) | 1.24B +101.0M (+8.9%) | 0.25% -0.006 pp | 0.68% -0.014 pp | USD93.73 +120.8% | 51 qtrs — |
| 45 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 5.95M -233.2K (-3.8%) | 1.23B +84.8M (+7.4%) | 0.24% -0.010 pp | 0.72% +0.064 pp | USD96.00 +115.6% | 59 qtrs — |
| 46 | CLEARBRIDGE INVESTMENTS, LLC | 5.61M +273.3K (+5.1%) | 1.16B +171.4M (+17.3%) | 0.23% +0.011 pp | 0.93% +0.184 pp | USD107.71 +92.1% | 62 qtrs — |
| 47 | NORDEA INVESTMENT MANAGEMENT AB | 5.46M -649.4K (-10.6%) | 1.13B +13.2M (+1.2%) | 0.22% -0.027 pp | 0.97% -0.008 pp | USD138.97 +48.9% | 88 qtrs — |
| 48 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 5.28M +248.0K (+4.9%) | 1.09B +161.7M (+17.3%) | 0.22% +0.010 pp | 0.74% +0.071 pp | USD156.14 +32.5% | 58 qtrs — |
| 49 | BANK OF MONTREAL /CAN/ | 5.19M +1.1M (+27.2%) | 1.07B +317.9M (+42.0%) | 0.21% +0.046 pp | 0.37% +0.082 pp | USD158.45 +30.6% | 51 qtrs — |
| 50 | LPL FINANCIAL LLC | 5.04M +54.3K (+1.1%) | 1.04B +118.6M (+12.8%) | 0.21% +0.002 pp | 0.29% +0.015 pp | USD155.50 +33.1% | 51 qtrs — |
| 51 | NATIONAL PENSION SERVICE | 4.99M +64.0K (+1.3%) | 1.03B +119.3M (+13.1%) | 0.21% +0.003 pp | 0.76% +0.055 pp | USD139.49 +48.4% | 46 qtrs — |
| 52 | STIFEL FINANCIAL CORP | 4.90M -159.7K (-3.2%) | 1.01B +76.0M (+8.1%) | 0.20% -0.007 pp | 0.91% +0.056 pp | USD146.45 +41.3% | 48 qtrs — |
| 53 | ENVESTNET ASSET MANAGEMENT INC | 4.56M -576.2K (-11.2%) | 943.51M -8.7M (-0.9%) | 0.19% -0.024 pp | 0.28% +0.006 pp | USD153.71 +34.6% | 51 qtrs — |
| 54 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4.51M +240.7K (+5.6%) | 933.76M +141.8M (+17.9%) | 0.19% +0.010 pp | 0.11% +0.017 pp | USD165.23 +25.2% | 51 qtrs — |
| 55 | BARCLAYS PLC | 4.46M -1.3M (-22.2%) | 922.00M -5.5M (-0.6%) | 0.18% -0.052 pp | 0.22% -0.017 pp | USD165.97 +24.7% | 51 qtrs — |
| 56 | MACKENZIE FINANCIAL CORP | 4.45M +806.1K (+22.1%) | 918.54M +243.3M (+36.0%) | 0.18% +0.033 pp | 1.09% +0.270 pp | USD150.76 +37.3% | 95 qtrs — |
| 57 | BAIRD FINANCIAL GROUP, INC. | 4.37M +93.4K (+2.2%) | 904.41M +111.4M (+14.0%) | 0.18% +0.004 pp | 1.41% +0.135 pp | USD145.29 +42.4% | 43 qtrs — |
| 58 | VICTORY CAPITAL MANAGEMENT INC | 4.20M -390.3K (-8.5%) | 870.10M -386.3M (-30.7%) | 0.17% -0.016 pp | 0.49% -0.244 pp | USD152.62 +35.6% | 50 qtrs — |
| 59 | RHUMBLINE ADVISERS | 3.97M -64.1K (-1.6%) | 822.42M +73.7M (+9.8%) | 0.16% -0.003 pp | 0.66% +0.064 pp | USD100.18 +106.6% | 55 qtrs — |
| 60 | HIGHTOWER ADVISORS, LLC | 3.95M -23.4K (-0.6%) | 817.19M +80.7M (+11.0%) | 0.16% -0.001 pp | 0.89% +0.058 pp | USD142.37 +45.4% | 67 qtrs — |
| 61 | AQR CAPITAL MANAGEMENT LLC | 3.88M -450.2K (-10.4%) | 802.18M +9.1M (+1.2%) | 0.16% -0.019 pp | 0.42% -0.088 pp | USD147.44 +40.4% | 91 qtrs — |
| 62 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 3.83M -67.4K (-1.7%) | 792.48M +70.0M (+9.7%) | 0.16% -0.003 pp | 0.79% +0.052 pp | USD100.58 +105.8% | 52 qtrs — |
| 63 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 3.76M +88.4K (+2.4%) | 779.06M +97.4M (+14.3%) | 0.16% +0.004 pp | 0.64% +0.080 pp | USD138.89 +49.0% | 108 qtrs — |
| 64 | MARSHALL WACE, LLP | 3.67M +84.1K (+2.3%) | 759.15M +94.6M (+14.2%) | 0.15% +0.004 pp | 0.69% +0.017 pp | USD171.60 +20.6% | 29 qtrs — |
| 65 | INDEPENDENT FRANCHISE PARTNERS LLP | 3.66M -932.6K (-20.3%) | 756.68M -94.2M (-11.1%) | 0.15% -0.038 pp | 4.81% -0.797 pp | USD135.65 +52.6% | 51 qtrs — |
| 66 | NEUBERGER BERMAN GROUP LLC | 3.63M -427.9K (-10.5%) | 752.24M -714.7K (-0.1%) | 0.15% -0.018 pp | 0.56% +0.010 pp | USD145.02 +42.7% | 58 qtrs — |
| 67 | CANADA PENSION PLAN INVESTMENT BOARD | 3.55M +75.0K (+2.2%) | 735.62M +90.4M (+14.0%) | 0.15% +0.003 pp | 0.49% +0.039 pp | USD157.15 +31.7% | 52 qtrs — |
| 68 | AMERICAN CENTURY COMPANIES INC | 3.50M -986.1K (-22.0%) | 723.32M -107.6M (-12.9%) | 0.14% -0.041 pp | 0.36% -0.059 pp | USD133.73 +54.8% | 51 qtrs — |
| 69 | DEKABANK DEUTSCHE GIROZENTRALE | 4.41M +— (+0.0%) | 709.25M -89.4M (-11.2%) | 0.18% +0.000 pp | 1.23% -0.118 pp | USD150.68 +37.3% | 66 qtrs — |
| 70 | PRINCIPAL FINANCIAL GROUP INC | 3.41M +28.4K (+0.8%) | 705.74M +78.7M (+12.5%) | 0.14% +0.001 pp | 0.36% +0.044 pp | USD109.53 +88.9% | 81 qtrs — |
| 71 | NEW YORK STATE COMMON RETIREMENT FUND | 2.96M -33.9K (-1.1%) | 613.40M +57.5M (+10.3%) | 0.12% -0.001 pp | 0.82% +0.100 pp | USD73.62 +181.1% | 103 qtrs — |
| 72 | CAPITAL RESEARCH GLOBAL INVESTORS | 2.87M -144.9K (-4.8%) | 593.91M +34.9M (+6.2%) | 0.12% -0.006 pp | 0.11% +0.005 pp | USD144.67 +43.0% | 51 qtrs — |
| 73 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 2.84M -2.5M (-46.5%) | 587.45M -396.3M (-40.3%) | 0.12% -0.102 pp | 0.51% -0.354 pp | USD165.17 +25.3% | 37 qtrs — |
| 74 | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 2.77M -772.0K (-21.8%) | 573.38M -83.5M (-12.7%) | 0.11% -0.032 pp | 0.97% -0.211 pp | USD143.45 +44.3% | 51 qtrs — |
| 75 | BAHL & GAYNOR INC | 2.74M +70.4K (+2.6%) | 566.62M +72.0M (+14.6%) | 0.11% +0.003 pp | 2.87% +0.412 pp | USD151.40 +36.7% | 51 qtrs — |
| 76 | CI PRIVATE WEALTH, LLC | 2.71M +110.3K (+4.2%) | 560.32M +79.3M (+16.5%) | 0.11% +0.005 pp | 0.75% -0.004 pp | USD172.78 +19.8% | 13 qtrs — |
| 77 | RUSSELL INVESTMENTS GROUP, LTD. | 2.69M -58.9K (-2.1%) | 557.23M +48.8M (+9.6%) | 0.11% -0.002 pp | 0.61% +0.030 pp | USD145.67 +42.1% | 37 qtrs — |
| 78 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 2.65M -479.9K (-15.3%) | 548.53M -19.9M (-3.5%) | 0.11% -0.020 pp | 0.95% +0.141 pp | USD130.95 +58.0% | 63 qtrs — |
| 79 | CITADEL ADVISORS LLC | 2.57M -525.5K (-17.0%) | 531.80M -42.1M (-7.3%) | 0.11% -0.022 pp | 0.08% -0.008 pp | USD168.68 +22.7% | 38 qtrs — |
| 80 | ABRDN PLC | 2.54M +48.0K (+1.9%) | 525.34M +69.2M (+15.2%) | 0.10% +0.002 pp | 0.81% +0.092 pp | USD152.96 +35.3% | 34 qtrs — |
| 81 | 1832 ASSET MANAGEMENT L.P. | 2.53M +1.5M (+147.0%) | 523.39M +333.5M (+175.7%) | 0.10% +0.062 pp | 0.40% +0.249 pp | USD181.21 +14.2% | 55 qtrs — |
| 82 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.51M +194.5K (+8.4%) | 519.22M +90.1M (+21.0%) | 0.10% +0.008 pp | 0.30% +0.034 pp | USD159.24 +30.0% | 36 qtrs — |
| 83 | US BANCORP \DE\ | 2.49M -42.1K (-1.7%) | 515.21M +45.8M (+9.8%) | 0.10% -0.002 pp | 0.60% +0.047 pp | USD92.19 +124.5% | 51 qtrs — |
| 84 | FIERA CAPITAL CORP | 2.46M -187.2K (-7.1%) | 508.73M +18.2M (+3.7%) | 0.10% -0.008 pp | 1.61% +0.028 pp | USD119.41 +73.3% | 59 qtrs — |
| 85 | SCHRODER INVESTMENT MANAGEMENT GROUP | 2.45M +421.3K (+20.8%) | 506.52M +130.8M (+34.8%) | 0.10% +0.017 pp | 0.39% +0.094 pp | USD153.51 +34.8% | 51 qtrs — |
| 86 | FEDERATED HERMES, INC. | 2.42M -1.0M (-29.7%) | 501.28M -137.7M (-21.6%) | 0.10% -0.042 pp | 0.84% -0.291 pp | USD158.28 +30.7% | 54 qtrs — |
| 87 | JANE STREET GROUP, LLC | 2.40M -791.5K (-24.8%) | 496.12M -95.1M (-16.1%) | 0.10% -0.033 pp | 0.07% -0.015 pp | USD170.76 +21.2% | 6 qtrs — |
| 88 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 2.39M +1.8M (+332.2%) | 493.70M +392.8M (+389.2%) | 0.10% +0.076 pp | 0.57% +0.305 pp | USD196.60 +5.3% | 51 qtrs — |
| 89 | KBC GROUP NV | 2.30M +410.7K (+21.8%) | 475.33M +125.6M (+35.9%) | 0.09% +0.017 pp | 1.08% +0.245 pp | USD175.80 +17.7% | 68 qtrs — |
| 90 | SWEDBANK AB | 2.30M +117.6K (+5.4%) | 474.98M +71.2M (+17.6%) | 0.09% +0.005 pp | 0.46% +0.050 pp | USD170.49 +21.4% | 20 qtrs — |
| 91 | PRUDENTIAL FINANCIAL INC | 2.27M +46.2K (+2.1%) | 469.51M +57.4M (+13.9%) | 0.09% +0.002 pp | 0.57% +0.077 pp | USD163.87 +26.3% | 85 qtrs — |
| 92 | ACR ALPINE CAPITAL RESEARCH, LLC | 2.24M +5.0K (+0.2%) | 462.96M +49.1M (+11.9%) | 0.09% +0.000 pp | 7.22% +0.147 pp | USD138.69 +49.2% | 51 qtrs — |
| 93 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.21M -52.7K (-2.3%) | 457.55M +37.8M (+9.0%) | 0.09% -0.002 pp | 0.69% +0.028 pp | USD170.21 +21.6% | 64 qtrs — |
| 94 | CITIGROUP INC | 2.20M +610.8K (+38.4%) | 455.83M +160.7M (+54.4%) | 0.09% +0.025 pp | 0.20% +0.070 pp | USD167.58 +23.5% | 108 qtrs — |
| 95 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 2.20M -125.6K (-5.4%) | 450.40M +19.7M (+4.6%) | 0.09% -0.005 pp | 0.73% +0.016 pp | USD144.91 +42.8% | 5 qtrs — |
| 96 | ACADIAN ASSET MANAGEMENT LLC | 2.16M -406.1K (-15.8%) | 446.41M -28.8M (-6.1%) | 0.09% -0.017 pp | 0.73% -0.097 pp | USD162.94 +27.0% | 50 qtrs — |
| 97 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 2.13M -47.3K (-2.2%) | 441.26M +37.1M (+9.2%) | 0.09% -0.002 pp | 0.78% +0.074 pp | USD101.94 +103.0% | 51 qtrs — |
| 98 | ENSIGN PEAK ADVISORS, INC | 2.13M -352.3K (-14.2%) | 439.98M -19.6M (-4.3%) | 0.09% -0.015 pp | 0.78% +0.023 pp | USD160.97 +28.6% | 25 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.76
Neutral
Ratio by volume
1.19
Neutral
Buys
91
Sells
119
Shares acquired
1.16M
Shares disposed
971.6K
Cash buys
—
Cash sales
16.00
Net activity
+188,296
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | REED JOHN C | Officer | M-Exempt | A | Common Stock | 25,255 | 0.00 | — | 35,913 | D | ↗ |
| 2026-04-23 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 6,215 | D | ↗ |
| 2026-04-23 | West Nadja | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 7,730 | D | ↗ |
| 2026-04-23 | WEINBERGER MARK A | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 12,010 | D | ↗ |
| 2026-04-23 | Pinto Daniel E | Director | A-Award | A | Deferred Share Units | 1,712 | 0.00 | — | 2,174 | D | ↗ |
| 2026-04-23 | McClellan Mark B. | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 21,279 | D | ↗ |
| 2026-04-23 | MORIKIS JOHN G | Director | A-Award | A | Deferred Share Units | 1,540 | 0.00 | — | 1,540 | D | ↗ |
| 2026-04-23 | Joly Hubert | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 9,184 | D | ↗ |
| 2026-04-23 | Johnson Paula A | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 5,359 | D | ↗ |
| 2026-04-23 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 15,488 | D | ↗ |
| 2026-04-23 | Doudna Jennifer A | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 10,899 | D | ↗ |
| 2026-04-23 | Beckerle Mary C | Director | A-Award | A | Deferred Share Units | 975 | 0.00 | — | 16,798 | D | ↗ |
| 2026-03-10 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 155 | 0.00 | — | 5,240 | D | ↗ |
| 2026-03-10 | Pinto Daniel E | Director | A-Award | A | Deferred Share Units | 129 | 0.00 | — | 462 | D | ↗ |
| 2026-03-10 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 206 | 0.00 | — | 14,513 | D | ↗ |
| 2026-02-27 | Decker Robert J | Officer | M-Exempt | A | Common Stock | 4,075 | 115.67 | 471.4K | 27,757 | D | ↗ |
| 2026-02-20 | Schmid Timothy | Officer | S-Sale | D | Common Stock | 1,322 | 245.66 | 324.8K | 25,447 | D | ↗ |
| 2026-02-18 | Schmid Timothy | Officer | M-Exempt | A | Common Stock | 13,625 | 115.67 | 1.58M | 40,394 | D | ↗ |
| 2026-02-17 | Wolk Joseph J | Officer | M-Exempt | A | Common Stock | 33,386 | 131.94 | 4.40M | 72,347 | D | ↗ |
| 2026-02-17 | Swanson James D. | Officer | S-Sale | D | Common Stock | 20,521 | 242.70 | 4.98M | 25,698 | D | ↗ |
| 2026-02-17 | REED JOHN C | Officer | M-Exempt | A | Common Stock | 21,721 | 157.92 | 3.43M | 34,662 | D | ↗ |
| 2026-02-17 | Broadhurst Vanessa | Officer | S-Sale | D | Common Stock | 6,197 | 243.39 | 1.51M | 23,003 | D | ↗ |
| 2026-02-15 | Wolk Joseph J | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 53,793 | 243.45 | 13.10M | 53,793 | D | ↗ |
| 2026-02-15 | Wengel Kathryn E | Officer | M-Exempt | D | Restricted Share Units | 606 | 0.00 | — | 606 | D | ↗ |
| 2026-02-15 | Taubert Jennifer L | Officer | M-Exempt | A | Common Stock | 1,847 | 0.00 | — | 195,396 | D | ↗ |
| 2026-02-15 | Swanson James D. | Officer | A-Award | A | Restricted Share Units | 1,397 | 0.00 | — | 1,397 | D | ↗ |
| 2026-02-15 | Schmid Timothy | Officer | M-Exempt | D | Restricted Share Units | 1,028 | 0.00 | — | 1,028 | D | ↗ |
| 2026-02-15 | REED JOHN C | Officer | F-InKind | D | Common Stock | 528 | 243.45 | 128.5K | 12,941 | D | ↗ |
| 2026-02-15 | Mulholland Kristen | Officer | M-Exempt | D | Restricted Share Units | 575 | 0.00 | — | 1,150 | D | ↗ |
| 2026-02-15 | Forminard Elizabeth | Officer | F-InKind | D | Common Stock | 492 | 243.45 | 119.8K | 23,049 | D | ↗ |
| 2026-02-15 | Duato Joaquin | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 131,734 | 243.45 | 32.07M | 131,734 | D | ↗ |
| 2026-02-15 | Decker Robert J | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 4,871 | 243.45 | 1.19M | 4,871 | D | ↗ |
| 2026-02-15 | Broadhurst Vanessa | Officer | M-Exempt | D | Restricted Share Units | 526 | 0.00 | — | 1,050 | D | ↗ |
| 2026-02-13 | Wolk Joseph J | Officer | M-Exempt | A | Common Stock | 37,463 | 0.00 | — | 51,463 | D | ↗ |
| 2026-02-13 | Wengel Kathryn E | Officer | M-Exempt | A | Common Stock | 13,706 | 0.00 | — | 120,096 | D | ↗ |
| 2026-02-13 | Taubert Jennifer L | Officer | F-InKind | D | Common Stock | 13,547 | 244.55 | 3.31M | 192,771 | D | ↗ |
| 2026-02-13 | Swanson James D. | Officer | M-Exempt | D | Performance Share Units | 9,412 | 0.00 | — | 0 | D | ↗ |
| 2026-02-13 | Schmid Timothy | Officer | F-InKind | D | Common Stock | 1,816 | 244.55 | 444.1K | 25,178 | D | ↗ |
| 2026-02-13 | Mulholland Kristen | Officer | M-Exempt | A | Common Stock | 410 | 0.00 | — | 16,819 | D | ↗ |
| 2026-02-13 | Forminard Elizabeth | Officer | M-Exempt | A | Common Stock | 13,706 | 0.00 | — | 29,591 | D | ↗ |
| 2026-02-13 | Duato Joaquin | Director / Officer | M-Exempt | D | Restricted Share Units | 3,469 | 0.00 | — | 0 | D | ↗ |
| 2026-02-13 | Decker Robert J | Officer | M-Exempt | D | Restricted Share Units | 312 | 0.00 | — | 0 | D | ↗ |
| 2026-02-13 | Broadhurst Vanessa | Officer | M-Exempt | D | Performance Share Units | 8,594 | 0.00 | — | 0 | D | ↗ |
| 2026-02-09 | Wolk Joseph J | Officer | A-Award | A | Performance Share Units | 37,463 | 0.00 | — | 37,463 | D | ↗ |
| 2026-02-09 | Wengel Kathryn E | Officer | A-Award | A | Performance Share Units | 13,706 | 0.00 | — | 13,706 | D | ↗ |
| 2026-02-09 | Taubert Jennifer L | Officer | A-Award | A | Performance Share Units | 27,412 | 0.00 | — | 27,412 | D | ↗ |
| 2026-02-09 | Swanson James D. | Officer | A-Award | A | Performance Share Units | 9,412 | 0.00 | — | 9,412 | D | ↗ |
| 2026-02-09 | Schmid Timothy | Officer | A-Award | A | Performance Share Units | 4,378 | 0.00 | — | 4,378 | D | ↗ |
| 2026-02-09 | Mulholland Kristen | Officer | A-Award | A | Performance Share Units | 3,602 | 0.00 | — | 3,602 | D | ↗ |
| 2026-02-09 | Forminard Elizabeth | Officer | A-Award | A | Performance Share Units | 13,706 | 0.00 | — | 13,706 | D | ↗ |
| 2026-02-09 | Duato Joaquin | Director / Officer | A-Award | A | Performance Share Units | 73,054 | 0.00 | — | 73,054 | D | ↗ |
| 2026-02-09 | Decker Robert J | Officer | A-Award | A | Performance Share Units | 2,741 | 0.00 | — | 2,741 | D | ↗ |
| 2026-02-09 | Broadhurst Vanessa | Officer | A-Award | A | Performance Share Units | 8,594 | 0.00 | — | 8,594 | D | ↗ |
| 2026-02-06 | Wengel Kathryn E | Officer | M-Exempt | D | Employee Stock Options (Right to Buy) | 38,945 | 101.87 | 3.97M | 0 | D | ↗ |
| 2026-02-06 | Schmid Timothy | Officer | M-Exempt | D | Employee Stock Options (Right to Buy) | 15,571 | 101.87 | 1.59M | 0 | D | ↗ |
| 2026-02-06 | Mulholland Kristen | Officer | M-Exempt | A | Common Stock | 5,625 | 101.87 | 573.0K | 19,744 | D | ↗ |
| 2026-02-05 | Forminard Elizabeth | Officer | M-Exempt | A | Common Stock | 8,921 | 129.51 | 1.16M | 21,774 | D | ↗ |
| 2026-01-26 | Duato Joaquin | Director / Officer | S-Sale | D | Common Stock | 51,218 | 220.99 | 11.32M | 79,634 | I | ↗ |
| 2025-12-09 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 186 | 0.00 | — | 5,058 | D | ↗ |
| 2025-12-09 | Pinto Daniel E | Director | A-Award | A | Deferred Share Units | 155 | 0.00 | — | 331 | D | ↗ |
| 2025-12-09 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 247 | 0.00 | — | 14,153 | D | ↗ |
| 2025-11-26 | MORIKIS JOHN G | Director | P-Purchase | A | Common Stock | 1,250 | 206.15 | 257.7K | 1,849 | D | ↗ |
| 2025-10-17 | REED JOHN C | Officer | S-Sale | D | Common Stock | 21,721 | 192.71 | 4.19M | 10,658 | D | ↗ |
| 2025-09-09 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 211 | 0.00 | — | 4,841 | D | ↗ |
| 2025-09-09 | Pinto Daniel E | Director | A-Award | A | Deferred Share Units | 175 | 0.00 | — | 175 | D | ↗ |
| 2025-09-09 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 281 | 0.00 | — | 13,817 | D | ↗ |
| 2025-09-08 | MORIKIS JOHN G | Director | — | — | Common Stock | 0 | 0.00 | — | 599 | D | ↗ |
| 2025-09-04 | Taubert Jennifer L | Officer | M-Exempt | A | Common Stock | 56,471 | 101.87 | 5.75M | 234,484 | D | ↗ |
| 2025-08-29 | Forminard Elizabeth | Officer | M-Exempt | D | Employee Stock Options (Right to Buy) | 11,521 | 115.67 | 1.33M | 0 | D | ↗ |
| 2025-08-22 | Duato Joaquin | Director / Officer | M-Exempt | A | Common Stock | 125,824 | 101.87 | 12.82M | 401,791 | D | ↗ |
| 2025-08-15 | Wolk Joseph J | Officer | M-Exempt | A | Common Stock | 16,820 | 101.87 | 1.71M | 30,820 | D | ↗ |
| 2025-07-17 | REED JOHN C | Officer | S-Sale | D | Common Stock | 19,137 | 163.55 | 3.13M | 10,658 | D | ↗ |
| 2025-07-01 | Pinto Daniel E | Director | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-06-10 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 231 | 0.00 | — | 4,597 | D | ↗ |
| 2025-06-10 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 322 | 0.00 | — | 13,438 | D | ↗ |
| 2025-05-01 | REED JOHN C | Officer | F-InKind | D | Common Stock | 11,002 | 156.31 | 1.72M | 29,795 | D | ↗ |
| 2025-04-24 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 4,330 | D | ↗ |
| 2025-04-24 | West Nadja | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 6,573 | D | ↗ |
| 2025-04-24 | WEINBERGER MARK A | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 10,737 | D | ↗ |
| 2025-04-24 | McClellan Mark B. | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 19,755 | D | ↗ |
| 2025-04-24 | Joly Hubert | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 7,987 | D | ↗ |
| 2025-04-24 | Johnson Paula A | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 4,266 | D | ↗ |
| 2025-04-24 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 13,007 | D | ↗ |
| 2025-04-24 | Doudna Jennifer A | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 9,656 | D | ↗ |
| 2025-04-24 | Beckerle Mary C | Director | A-Award | A | Deferred Share Units | 1,316 | 0.00 | — | 15,395 | D | ↗ |
| 2025-03-18 | Duato Joaquin | Director / Officer | G-Gift | D | Common Stock | 130,852 | 0.00 | — | 275,967 | D | ↗ |
| 2025-03-04 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 188 | 0.00 | — | 3,014 | D | ↗ |
| 2025-03-04 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 75 | 0.00 | — | 14,306 | D | ↗ |
| 2025-02-25 | Decker Robert J | Officer | M-Exempt | A | Common Stock | 6,999 | 101.87 | 713.0K | 28,000 | D | ↗ |
| 2025-02-18 | Wolk Joseph J | Officer | F-InKind | D | Common Stock | 768 | 156.15 | 119.9K | 5,345 | D | ↗ |
| 2025-02-18 | Wengel Kathryn E | Officer | F-InKind | D | Common Stock | 200 | 156.15 | 31.2K | 90,837 | D | ↗ |
| 2025-02-18 | Taubert Jennifer L | Officer | F-InKind | D | Common Stock | 651 | 156.15 | 101.7K | 170,459 | D | ↗ |
| 2025-02-18 | Swanson James D. | Officer | F-InKind | D | Common Stock | 141 | 156.15 | 22.0K | 16,621 | D | ↗ |
| 2025-02-18 | Schmid Timothy | Officer | S-Sale | D | Common Stock | 403 | 156.15 | 62.9K | 15,098 | D | ↗ |
| 2025-02-18 | REED JOHN C | Officer | F-InKind | D | Common Stock | 385 | 156.15 | 60.1K | 15,542 | D | ↗ |
| 2025-02-18 | Mulholland Kristen | Officer | F-InKind | D | Common Stock | 120 | 156.15 | 18.7K | 12,975 | D | ↗ |
| 2025-02-18 | Forminard Elizabeth | Officer | F-InKind | D | Common Stock | 307 | 156.15 | 47.9K | 10,014 | D | ↗ |
| 2025-02-18 | Duato Joaquin | Director / Officer | F-InKind | D | Common Stock | 1,602 | 156.15 | 250.2K | 395,923 | D | ↗ |
| 2025-02-18 | Decker Robert J | Officer | F-InKind | D | Common Stock | 94 | 156.15 | 14.7K | 20,022 | D | ↗ |
| 2025-02-18 | Broadhurst Vanessa | Officer | F-InKind | D | Common Stock | 158 | 156.15 | 24.7K | 21,681 | D | ↗ |
| 2025-02-15 | Wolk Joseph J | Officer | A-Award | A | Restricted Share Units | 5,632 | 0.00 | — | 5,632 | D | ↗ |
| 2025-02-15 | Wengel Kathryn E | Officer | M-Exempt | D | Restricted Share Units | 607 | 0.00 | — | 1,212 | D | ↗ |
| 2025-02-15 | Taubert Jennifer L | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 89,781 | 156.15 | 14.02M | 89,781 | D | ↗ |
| 2025-02-15 | Swanson James D. | Officer | M-Exempt | A | Common Stock | 492 | 0.00 | — | 16,762 | D | ↗ |
| 2025-02-15 | Schmid Timothy | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 49,878 | 156.15 | 7.79M | 49,878 | D | ↗ |
| 2025-02-15 | REED JOHN C | Officer | M-Exempt | A | Common Stock | 1,350 | 0.00 | — | 15,927 | D | ↗ |
| 2025-02-15 | Mulholland Kristen | Officer | M-Exempt | A | Common Stock | 419 | 0.00 | — | 13,095 | D | ↗ |
| 2025-02-15 | Forminard Elizabeth | Officer | M-Exempt | D | Restricted Share Units | 961 | 0.00 | — | 1,922 | D | ↗ |
| 2025-02-15 | Duato Joaquin | Director / Officer | M-Exempt | D | Restricted Share Units | 3,682 | 0.00 | — | 7,364 | D | ↗ |
| 2025-02-15 | Decker Robert J | Officer | M-Exempt | D | Restricted Share Units | 339 | 0.00 | — | 677 | D | ↗ |
| 2025-02-15 | Broadhurst Vanessa | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 25,538 | 156.15 | 3.99M | 25,538 | D | ↗ |
| 2025-02-14 | Wolk Joseph J | Officer | F-InKind | D | Common Stock | 507 | 155.26 | 78.7K | 1,272 | D | ↗ |
| 2025-02-14 | Wengel Kathryn E | Officer | M-Exempt | A | Common Stock | 1,530 | 0.00 | — | 90,910 | D | ↗ |
| 2025-02-14 | Taubert Jennifer L | Officer | M-Exempt | A | Common Stock | 15,465 | 0.00 | — | 185,924 | D | ↗ |
| 2025-02-14 | Swanson James D. | Officer | M-Exempt | D | Performance Share Units | 3,118 | 0.00 | — | 0 | D | ↗ |
| 2025-02-14 | Schmid Timothy | Officer | — | D | Employee Stock Options (Right to Buy) | 17,431 | 165.89 | 2.89M | 0 | — | ↗ |
| 2025-02-14 | Mulholland Kristen | Officer | M-Exempt | A | Common Stock | 1,007 | 0.00 | — | 12,966 | D | ↗ |
| 2025-02-14 | Forminard Elizabeth | Officer | F-InKind | D | Common Stock | 267 | 156.71 | 41.8K | 9,360 | D | ↗ |
| 2025-02-14 | Duato Joaquin | Director / Officer | M-Exempt | A | Common Stock | 19,282 | 0.00 | — | 415,205 | D | ↗ |
| 2025-02-14 | Decker Robert J | Officer | M-Exempt | D | Restricted Share Units | 850 | 0.00 | — | 0 | D | ↗ |
| 2025-02-14 | Broadhurst Vanessa | Officer | M-Exempt | A | Common Stock | 2,910 | 0.00 | — | 24,591 | D | ↗ |
| 2025-02-13 | Wolk Joseph J | Officer | M-Exempt | D | Restricted Share Units | 1,779 | 0.00 | — | 1,779 | D | ↗ |
| 2025-02-13 | Wengel Kathryn E | Officer | M-Exempt | A | Common Stock | 651 | 0.00 | — | 89,603 | D | ↗ |
| 2025-02-13 | Taubert Jennifer L | Officer | M-Exempt | D | Restricted Share Units | 1,302 | 0.00 | — | 1,302 | D | ↗ |
| 2025-02-13 | Swanson James D. | Officer | M-Exempt | D | Restricted Share Units | 447 | 0.00 | — | 447 | D | ↗ |
| 2025-02-13 | Schmid Timothy | Officer | M-Exempt | A | Common Stock | 499 | 0.00 | — | 13,539 | D | ↗ |
| 2025-02-13 | Mulholland Kristen | Officer | M-Exempt | A | Common Stock | 411 | 0.00 | — | 12,100 | D | ↗ |
| 2025-02-13 | Forminard Elizabeth | Officer | M-Exempt | A | Common Stock | 651 | 0.00 | — | 8,991 | D | ↗ |
| 2025-02-13 | Duato Joaquin | Director / Officer | M-Exempt | A | Common Stock | 3,470 | 0.00 | — | 392,498 | D | ↗ |
| 2025-02-13 | Decker Robert J | Officer | M-Exempt | D | Restricted Share Units | 312 | 0.00 | — | 312 | D | ↗ |
| 2025-02-13 | Broadhurst Vanessa | Officer | M-Exempt | D | Restricted Share Units | 408 | 0.00 | — | 408 | D | ↗ |
| 2025-02-10 | Wolk Joseph J | Officer | A-Award | A | Performance Share Units | 15,316 | 0.00 | — | 15,316 | D | ↗ |
| 2025-02-10 | Wengel Kathryn E | Officer | A-Award | A | Performance Share Units | 5,837 | 0.00 | — | 5,837 | D | ↗ |
| 2025-02-10 | Taubert Jennifer L | Officer | A-Award | A | Performance Share Units | 15,465 | 0.00 | — | 15,465 | D | ↗ |
| 2025-02-10 | Swanson James D. | Officer | A-Award | A | Performance Share Units | 3,118 | 0.00 | — | 3,118 | D | ↗ |
| 2025-02-10 | Schmid Timothy | Officer | A-Award | A | Performance Share Units | 2,806 | 0.00 | — | 2,806 | D | ↗ |
| 2025-02-10 | Mulholland Kristen | Officer | A-Award | A | Performance Share Units | 1,601 | 0.00 | — | 1,601 | D | ↗ |
| 2025-02-10 | Forminard Elizabeth | Officer | A-Award | A | Performance Share Units | 1,352 | 0.00 | — | 1,352 | D | ↗ |
| 2025-02-10 | Duato Joaquin | Director / Officer | A-Award | A | Performance Share Units | 19,282 | 0.00 | — | 19,282 | D | ↗ |
| 2025-02-10 | Decker Robert J | Officer | A-Award | A | Performance Share Units | 1,351 | 0.00 | — | 1,351 | D | ↗ |
| 2025-02-10 | Broadhurst Vanessa | Officer | A-Award | A | Performance Share Units | 2,910 | 0.00 | — | 2,910 | D | ↗ |
| 2025-02-07 | Wolk Joseph J | Officer | S-Sale | D | Common Stock | 13,015 | 153.89 | 2.00M | 0 | D | ↗ |
| 2025-02-07 | Wengel Kathryn E | Officer | M-Exempt | D | Employee Stock Options (Right to Buy) | 32,762 | 100.06 | 3.28M | 0 | D | ↗ |
| 2025-02-07 | Taubert Jennifer L | Officer | M-Exempt | A | Common Stock | 58,504 | 100.06 | 5.85M | 213,355 | D | ↗ |
| 2025-02-07 | Duato Joaquin | Director / Officer | F-InKind | D | Common Stock | 100,643 | 153.12 | 15.41M | 389,028 | D | ↗ |
| 2024-12-31 | Woods Eugene A. | Director | — | — | Common Stock | 0 | 0.00 | — | 150 | I | ↗ |
| 2024-12-12 | WEINBERGER MARK A | Director | P-Purchase | A | Common Stock | 1,000 | 147.22 | 147.2K | 1,000 | D | ↗ |
| 2024-12-10 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 209 | 0.00 | — | 2,805 | D | ↗ |
| 2024-12-10 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 335 | 0.00 | — | 11,380 | D | ↗ |
| 2024-10-17 | Wolk Joseph J | Officer | G-Gift | A | Common Stock | 68,835 | 0.00 | — | 68,835 | I | ↗ |
| 2024-10-01 | Mulholland Kristen | Officer | — | — | Employee Stock Options (Right to Buy) | 10,191 | 162.75 | 1.66M | 0 | D | ↗ |
| 2024-09-10 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 188 | 0.00 | — | 2,574 | — | ↗ |
| 2024-09-10 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 303 | 0.00 | — | 10,955 | — | ↗ |
| 2024-08-30 | Decker Robert J | Officer | S-Sale | D | Common Stock | 5,635 | 165.06 | 930.1K | 18,973 | — | ↗ |
| 2024-07-08 | Broadhurst Vanessa | Officer | M-Exempt | A | Common Stock | 9,809 | 0.00 | — | 24,852 | — | ↗ |
| 2024-07-01 | Broadhurst Vanessa | Officer | — | D | Restricted Share Units | 9,809 | 0.00 | — | 0 | — | ↗ |
| 2024-06-04 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 211 | 0.00 | — | 2,368 | — | ↗ |
| 2024-06-04 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 315 | 0.00 | — | 10,573 | — | ↗ |
| 2024-05-22 | Wolk Joseph J | Officer | G-Gift | D | Common Stock | 55 | 0.00 | — | 68,835 | D | ↗ |
| 2024-05-01 | REED JOHN C | Officer | M-Exempt | D | Restricted Share Units | 22,255 | 0.00 | — | 53,510 | — | ↗ |
| 2024-04-25 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 2,139 | — | ↗ |
| 2024-04-25 | West Nadja | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 5,094 | — | ↗ |
| 2024-04-25 | WEINBERGER MARK A | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 9,129 | — | ↗ |
| 2024-04-25 | McClellan Mark B. | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 17,868 | — | ↗ |
| 2024-04-25 | MULCAHY ANNE M | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 21,471 | — | ↗ |
| 2024-04-25 | Joly Hubert | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 6,464 | — | ↗ |
| 2024-04-25 | Johnson Paula A | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 2,859 | — | ↗ |
| 2024-04-25 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 10,173 | — | ↗ |
| 2024-04-25 | Doudna Jennifer A | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 8,082 | — | ↗ |
| 2024-04-25 | DAVIS D SCOTT | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 15,604 | D | ↗ |
| 2024-04-25 | Beckerle Mary C | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 13,643 | — | ↗ |
| 2024-04-25 | Adamczyk Darius | Director | A-Award | A | Deferred Share Units | 1,386 | 0.00 | — | 3,713 | — | ↗ |
| 2024-03-13 | Broadhurst Vanessa | Officer | S-Sale | D | Common Stock | 8,891 | 162.16 | 1.44M | 15,043 | — | ↗ |
| 2024-03-05 | Woods Eugene A. | Director | A-Award | A | Deferred Share Units | 262 | 0.00 | — | 753 | — | ↗ |
| 2024-03-05 | HEWSON MARILLYN A | Director | A-Award | A | Deferred Share Units | 235 | 0.00 | — | 8,788 | — | ↗ |
| 2024-02-28 | Mammen Mathai | Officer | — | D | Employee Stock Options (Right to Buy) | 43,149 | 164.62 | 7.10M | 0 | — | ↗ |
| 2024-02-15 | Wolk Joseph J | Officer | A-Award | A | Restricted Share Units | 5,913 | 0.00 | — | 5,913 | — | ↗ |
| 2024-02-15 | Wengel Kathryn E | Officer | A-Award | A | Restricted Share Units | 1,819 | 0.00 | — | 1,819 | — | ↗ |
| 2024-02-15 | Taubert Jennifer L | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 76,981 | 157.92 | 12.16M | 76,981 | — | ↗ |
| 2024-02-15 | Swanson James D. | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 23,745 | 157.92 | 3.75M | 23,745 | — | ↗ |
| 2024-02-15 | Schmid Timothy | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 49,658 | 157.92 | 7.84M | 49,658 | — | ↗ |
| 2024-02-15 | REED JOHN C | Officer | A-Award | A | Restricted Share Units | 4,048 | 0.00 | — | 4,048 | — | ↗ |
| 2024-02-15 | Hait William | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 34,696 | 157.92 | 5.48M | 34,696 | — | ↗ |
| 2024-02-15 | Forminard Elizabeth | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 46,406 | 157.92 | 7.33M | 46,406 | — | ↗ |
| 2024-02-15 | Fasolo Peter | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 40,551 | 157.92 | 6.40M | 40,551 | — | ↗ |
| 2024-02-15 | Duato Joaquin | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 177,816 | 157.92 | 28.08M | 177,816 | — | ↗ |
| 2024-02-15 | Decker Robert J | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 8,175 | 157.92 | 1.29M | 8,175 | — | ↗ |
| 2024-02-15 | Broadhurst Vanessa | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 23,745 | 157.92 | 3.75M | 23,745 | — | ↗ |
| 2024-02-13 | Wolk Joseph J | Officer | M-Exempt | A | Common Stock | 1,780 | 0.00 | — | 69,663 | — | ↗ |
| 2024-02-13 | Wengel Kathryn E | Officer | M-Exempt | A | Common Stock | 651 | 0.00 | — | 82,599 | — | ↗ |
| 2024-02-13 | Taubert Jennifer L | Officer | M-Exempt | A | Common Stock | 1,302 | 0.00 | — | 155,517 | — | ↗ |
| 2024-02-13 | Swanson James D. | Officer | M-Exempt | A | Common Stock | 447 | 0.00 | — | 14,765 | — | ↗ |
| 2024-02-13 | Schmid Timothy | Officer | M-Exempt | D | Restricted Share Units | 499 | 0.00 | — | 998 | — | ↗ |
| 2024-02-13 | Hait William | Officer | M-Exempt | A | Common Stock | 834 | 0.00 | — | 39,074 | — | ↗ |
| 2024-02-13 | Forminard Elizabeth | Officer | M-Exempt | A | Common Stock | 651 | 0.00 | — | 8,576 | — | ↗ |
| 2024-02-13 | Fasolo Peter | Officer | M-Exempt | D | Restricted Share Units | 925 | 0.00 | — | 1,848 | — | ↗ |
| 2024-02-13 | Duato Joaquin | Director / Officer | M-Exempt | A | Common Stock | 3,470 | 0.00 | — | 364,809 | — | ↗ |
| 2024-02-13 | Decker Robert J | Officer | F-InKind | D | Common Stock | 86 | 157.85 | 13.6K | 18,973 | — | ↗ |
| 2024-02-13 | Broadhurst Vanessa | Officer | M-Exempt | A | Common Stock | 408 | 0.00 | — | 24,143 | — | ↗ |
| 2024-02-12 | Wolk Joseph J | Officer | M-Exempt | A | Common Stock | 3,716 | 0.00 | — | 78,699 | — | ↗ |
Executive team
Top executives
EBIT / Employee
236.8K
Shares Outstanding
2.41B
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | J. Duato Chairman/CEO | 1.60M | — | 15.03M | 5.93M | 4.30M | 5.90M | 32.76M | 63.97% | ↗ |
| 2 | 2025 | J. Wolk EVP, CFO | 1.24M | — | 6.26M | 2.47M | 1.86M | 2.57M | 14.41M | 60.63% | ↗ |
| 3 | 2025 | J. Taubert EVP, WWC Innovative Medicine | 1.22M | — | 6.16M | 2.43M | 2.00M | 2.22M | 14.03M | 61.23% | ↗ |
| 4 | 2025 | J. Reed EVP, Innovative Medicine, R&D | 1.22M | — | 6.16M | 2.43M | 1.81M | 593.1K | 12.21M | 70.33% | ↗ |
| 5 | 2025 | T. Schmid EVP, WWC, MedTech | 942.3K | — | 3.42M | 1.35M | 1.51M | 2.11M | 9.34M | 51.11% | ↗ |
| 6 | 2024 | J. Duato Chairman/CEO | 1.60M | — | 10.79M | 4.92M | 3.98M | 3.01M | 24.30M | 64.63% | ↗ |
| 7 | 2024 | J. Wolk EVP, CFO | 1.21M | — | 5.77M | 2.63M | 1.77M | 1.22M | 12.62M | 66.65% | ↗ |
| 8 | 2024 | T. Schmid EVP, WWC, MedTech | 896.3K | — | 3.01M | 1.37M | 1.39M | 5.19M | 11.86M | 36.98% | ↗ |
| 9 | 2024 | J. Taubert EVP, WWC Innovative Medicine | 1.19M | — | 4.67M | 2.13M | 1.91M | 1.29M | 11.19M | 60.77% | ↗ |
| 10 | 2024 | J. Reed EVP, Innovative Medicine, R&D | 1.19M | — | 3.95M | 1.80M | 1.73M | 631.0K | 9.30M | 61.86% | ↗ |
| 11 | 2023 | J. Duato Chairman/CEO | 1.58M | — | 11.18M | 4.80M | 4.38M | 6.45M | 28.40M | 56.27% | ↗ |
| 12 | 2023 | J. Reed EVP, Innovative Medicine, R&D | 840.4K | 5.70M | 11.70M | — | 1.72M | 687.0K | 20.65M | 56.67% | ↗ |
| 13 | 2023 | J. Wolk EVP, CFO | 1.15M | — | 5.77M | 2.46M | 1.93M | 2.61M | 13.91M | 59.12% | ↗ |
| 14 | 2023 | J. Taubert EVP, WWC Innovative Medicine | 1.13M | — | 4.25M | 1.80M | 1.90M | 1.92M | 11.00M | 54.99% | ↗ |
| 15 | 2023 | A. McEvoy Former EVP, WWC MedTech | 1.06M | — | 4.02M | 1.71M | 1.26M | 1.36M | 9.40M | 60.86% | ↗ |
| 16 | 2023 | P. Fasolo EVP, Chief Human Resources Officer | 877.7K | — | 3.00M | 1.28M | 1.16M | 1.19M | 7.50M | 57.02% | ↗ |
| 17 | 2022 | J. Duato Chairman/CEO | 1.49M | — | 5.94M | 2.32M | 3.08M | 269.0K | 13.10M | 63.05% | ↗ |
| 18 | 2022 | J. Wolk EVP, CFO | 1.01M | — | 4.72M | 1.84M | 1.18M | 76.0K | 8.82M | 74.36% | ↗ |
| 19 | 2022 | J. Taubert EVP, WWC Innovative Medicine | 1.01M | — | 4.76M | 1.86M | 1.09M | 53.3K | 8.78M | 75.44% | ↗ |
| 20 | 2022 | J. Taubert EVP, Worldwide Chair Pharmaceuticals | 1.01M | — | 4.76M | 1.86M | 1.09M | 53.3K | 8.78M | 75.44% | ↗ |
| 21 | 2022 | A. McEvoy Former EVP, WWC MedTech | 984.6K | — | 3.94M | 1.54M | 890.3K | 44.3K | 7.39M | 74.03% | ↗ |
| 22 | 2022 | A. McEvoy EVP, Worldwide Chair MedTech | 984.6K | — | 3.94M | 1.54M | 890.3K | 44.3K | 7.39M | 74.03% | ↗ |
| 23 | 2022 | T. Mongon EVP, Worldwide Chair Consumer Health | 917.3K | — | 3.68M | 1.44M | 798.0K | 258.9K | 7.09M | 72.16% | ↗ |
| 24 | 2021 | Alex Gorsky Chairman/CEO | 1.65M | — | 14.79M | 5.07M | 4.25M | 980.0K | 26.74M | 74.26% | ↗ |
| 25 | 2021 | Paulus Stoffels VC of the Executive Committee, CSO | 1.22M | — | 7.49M | 2.57M | 2.66M | 1.07M | 15.01M | 67.00% | ↗ |
| 26 | 2021 | Joaquin Duato Vice Chairman of the Executive Committee | 1.03M | — | 7.00M | 2.39M | 2.32M | 1.06M | 13.81M | 68.06% | ↗ |
| 27 | 2021 | J. Duato Chairman/CEO | 1.03M | — | 7.00M | 2.39M | 2.32M | 1.06M | 13.81M | 68.06% | ↗ |
| 28 | 2021 | J. Wolk EVP, CFO | 938.1K | — | 4.88M | 1.69M | 1.56M | 1.89M | 10.95M | 59.95% | ↗ |
| 29 | 2021 | Joseph Wolk EVP, CFO | 938.1K | — | 4.88M | 1.69M | 1.56M | 1.89M | 10.95M | 59.95% | ↗ |
| 30 | 2021 | J. Taubert EVP, WWC Innovative Medicine | 938.1K | — | 4.95M | 1.71M | 1.51M | 1.12M | 10.23M | 65.13% | ↗ |
| 31 | 2021 | J. Taubert EVP, Worldwide Chair Pharmaceuticals | 938.1K | — | 4.95M | 1.71M | 1.51M | 1.12M | 10.23M | 65.13% | ↗ |
| 32 | 2021 | Jennifer Taubert EVP, Worldwide Chair Pharmaceuticals | 938.1K | — | 4.95M | 1.71M | 1.51M | 1.12M | 10.23M | 65.13% | ↗ |
| 33 | 2020 | Alex Gorsky Chairman/CEO | 1.65M | — | 13.76M | 4.38M | 3.15M | 6.64M | 29.58M | 61.34% | ↗ |
| 34 | 2020 | Paulus Stoffels VC of the Executive Committee, CSO | 1.22M | — | 6.87M | 2.20M | 2.06M | 4.09M | 16.44M | 55.19% | ↗ |
| 35 | 2020 | J. Duato Chairman/CEO | 1.02M | — | 6.80M | 2.19M | 1.82M | 3.79M | 15.63M | 57.54% | ↗ |
| 36 | 2020 | Joaquin Duato Vice Chairman of the Executive Committee | 1.02M | — | 6.80M | 2.19M | 1.82M | 3.79M | 15.63M | 57.54% | ↗ |
| 37 | 2020 | Joseph Wolk EVP, CFO | 885.4K | — | 4.16M | 1.45M | 1.04M | 2.65M | 10.20M | 55.05% | ↗ |
| 38 | 2020 | J. Wolk EVP, CFO | 885.4K | — | 4.16M | 1.45M | 1.04M | 2.65M | 10.20M | 55.05% | ↗ |
| 39 | 2020 | J. Taubert EVP, Worldwide Chair Pharmaceuticals | 884.6K | — | 4.47M | 1.50M | 990.1K | 1.69M | 9.53M | 62.62% | ↗ |
| 40 | 2020 | Jennifer Taubert EVP, Worldwide Chair Pharmaceuticals | 884.6K | — | 4.47M | 1.50M | 990.1K | 1.69M | 9.53M | 62.62% | ↗ |
| 41 | 2019 | Alex Gorsky Chairman/CEO | 1.65M | — | 9.96M | 4.05M | 3.69M | 6.02M | 25.37M | 55.22% | ↗ |
| 42 | 2019 | Paulus Stoffels VC of the Executive Committee, CSO | 1.22M | — | 4.82M | 2.04M | 2.39M | 3.59M | 14.07M | 48.80% | ↗ |
| 43 | 2019 | Joaquin Duato Vice Chairman of the Executive Committee | 969.6K | — | 4.62M | 1.97M | 2.30M | 3.56M | 13.42M | 49.16% | ↗ |
| 44 | 2019 | Joseph Wolk EVP, CFO | 796.5K | — | 2.38M | 1.18M | 1.13M | 2.01M | 7.50M | 47.50% | ↗ |
| 45 | 2019 | Jennifer Taubert EVP, Worldwide Chair | 796.2K | — | 2.63M | 1.20M | 1.18M | 1.30M | 7.10M | 53.90% | ↗ |
| 46 | 2019 | Jennifer Taubert EVP, Worldwide Chair Pharmaceuticals | 796.2K | — | 2.63M | 1.20M | 1.18M | 1.30M | 7.10M | 53.90% | ↗ |
| 47 | 2018 | Alex Gorsky Chairman/CEO | 1.64M | — | 10.32M | 4.31M | 3.57M | 259.7K | 20.10M | 72.77% | ↗ |
| 48 | 2018 | Sandra Peterson Former EVP, Group Worldwide Chairman | 808.5K | — | 4.00M | 1.69M | 1.01M | 3.17M | 10.68M | 53.29% | ↗ |
| 49 | 2018 | Paulus Stoffels VC of the Executive Committee, CSO | 1.18M | — | 4.67M | 2.01M | 2.19M | 544.9K | 10.59M | 63.04% | ↗ |
| 50 | 2018 | Joaquin Duato Vice Chairman of the Executive Committee | 934.0K | — | 4.28M | 1.89M | 2.01M | 170.9K | 9.28M | 66.45% | ↗ |
| 51 | 2018 | Dominic Caruso Former EVP, CFO | 630.5K | — | 3.68M | 1.55M | 727.5K | 131.3K | 6.71M | 77.81% | ↗ |
| 52 | 2018 | Michael Ullmann EVP, General Counsel | 788.1K | — | 1.97M | 828.0K | 1.28M | 474.7K | 5.34M | 52.41% | ↗ |
| 53 | 2018 | Joseph Wolk EVP, CFO | 597.5K | — | 670.1K | 216.9K | 749.7K | 473.9K | 2.71M | 32.75% | ↗ |
| 54 | 2017 | Alex Gorsky Chairman/CEO | 1.60M | — | 12.35M | 5.05M | 3.60M | 7.20M | 29.80M | 58.41% | ↗ |
| 55 | 2017 | Alex Gorsky Chairman, CEO | 1.60M | — | 12.35M | 5.05M | 3.60M | 7.20M | 29.80M | 58.41% | ↗ |
| 56 | 2017 | Joaquin Duato Vice Chairman of the Executive Committee | 897.3K | — | 11.48M | 1.65M | 1.93M | 3.40M | 19.36M | 67.84% | ↗ |
| 57 | 2017 | Joaquin Duato EVP, Worldwide Chairman Pharmaceuticals | 897.3K | — | 11.48M | 1.65M | 1.93M | 3.40M | 19.36M | 67.84% | ↗ |
| 58 | 2017 | Sandra Peterson EVP, Group Worldwide Chairman | 1.06M | — | 12.03M | 1.86M | 1.27M | 960.8K | 17.18M | 80.86% | ↗ |
| 59 | 2017 | Sandra Peterson Former EVP, Group Worldwide Chairman | 1.06M | — | 12.03M | 1.86M | 1.27M | 960.8K | 17.18M | 80.86% | ↗ |
| 60 | 2017 | Paulus Stoffels VC of the Executive Committee, CSO | 1.17M | — | 4.63M | 1.86M | 2.14M | 3.78M | 13.58M | 47.79% | ↗ |
| 61 | 2017 | Paulus Stoffels EVP, CSO | 1.17M | — | 4.63M | 1.86M | 2.14M | 3.78M | 13.58M | 47.79% | ↗ |
| 62 | 2017 | Dominic Caruso Former EVP, CFO | 932.6K | — | 4.26M | 1.76M | 2.16M | 2.63M | 11.74M | 51.30% | ↗ |
| 63 | 2017 | Dominic Caruso EVP, CFO | 932.6K | — | 4.26M | 1.76M | 2.16M | 2.63M | 11.74M | 51.30% | ↗ |
| 64 | 2016 | Alex Gorsky Chairman/CEO | 1.60M | — | 10.61M | 4.12M | 4.65M | 5.89M | 26.87M | 54.81% | ↗ |
| 65 | 2016 | Alex Gorsky Chairman, CEO | 1.60M | — | 10.61M | 4.12M | 4.65M | 5.89M | 26.87M | 54.81% | ↗ |
| 66 | 2016 | Paulus Stoffels VC of the Executive Committee, CSO | 1.14M | — | 4.38M | 1.75M | 2.43M | 3.02M | 12.73M | 48.20% | ↗ |
| 67 | 2016 | Paulus Stoffels EVP, CSO | 1.14M | — | 4.38M | 1.75M | 2.43M | 3.02M | 12.73M | 48.20% | ↗ |
| 68 | 2016 | Dominic Caruso Former EVP, CFO | 909.5K | — | 3.62M | 1.43M | 2.76M | 2.59M | 11.30M | 44.67% | ↗ |
| 69 | 2016 | Dominic Caruso EVP, CFO | 909.5K | — | 3.62M | 1.43M | 2.76M | 2.59M | 11.30M | 44.67% | ↗ |
| 70 | 2016 | Joaquin Duato EVP, Worldwide Chairman Pharmaceuticals | 875.0K | — | 3.20M | 1.26M | 2.16M | 2.61M | 10.10M | 44.12% | ↗ |
| 71 | 2016 | Joaquin Duato Vice Chairman of the Executive Committee | 875.0K | — | 3.20M | 1.26M | 2.16M | 2.61M | 10.10M | 44.12% | ↗ |
| 72 | 2016 | Joaquin Duato EVP, Worldwide Chairman, Pharmaceuticals | 875.0K | — | 3.20M | 1.26M | 2.16M | 2.61M | 10.10M | 44.12% | ↗ |
| 73 | 2016 | Sandra Peterson EVP, Group Worldwide Chairman | 963.5K | — | 3.90M | 1.54M | 1.60M | 733.2K | 8.73M | 62.25% | ↗ |
| 74 | 2016 | Sandra Peterson Former EVP, Group Worldwide Chairman | 963.5K | — | 3.90M | 1.54M | 1.60M | 733.2K | 8.73M | 62.25% | ↗ |
| 75 | 2015 | Alex Gorsky Chairman, CEO | 1.61M | — | 10.69M | 4.56M | 4.01M | 2.92M | 23.80M | 64.11% | ↗ |
| 76 | 2015 | Alex Gorsky Chairman/CEO | 1.61M | — | 10.69M | 4.56M | 4.01M | 2.92M | 23.80M | 64.11% | ↗ |
| 77 | 2015 | Paulus Stoffels Chief Scientific Officer; Worldwide Chairman, Pharmaceuticals | 1.16M | — | 4.21M | 1.82M | 2.17M | 1.42M | 10.79M | 55.93% | ↗ |
| 78 | 2015 | Paulus Stoffels EVP, CSO | 1.16M | — | 4.21M | 1.82M | 2.17M | 1.42M | 10.79M | 55.93% | ↗ |
| 79 | 2015 | Dominic Caruso EVP, CFO | 922.6K | — | 3.50M | 1.46M | 2.77M | 1.04M | 9.69M | 51.15% | ↗ |
| 80 | 2015 | Dominic Caruso VP, Finance, CFO | 922.6K | — | 3.50M | 1.46M | 2.77M | 1.04M | 9.69M | 51.15% | ↗ |
| 81 | 2015 | Sandra Peterson Group Worldwide Chairman | 908.7K | — | 3.50M | 1.57M | 1.13M | 514.0K | 7.63M | 66.59% | ↗ |
| 82 | 2015 | Sandra Peterson EVP, Group Worldwide Chairman | 908.7K | — | 3.50M | 1.57M | 1.13M | 514.0K | 7.63M | 66.59% | ↗ |
| 83 | 2015 | Michael Ullmann VP, General Counsel | 645.4K | — | 1.96M | 819.0K | 1.16M | 1.09M | 5.68M | 49.00% | ↗ |
| 84 | 2014 | Alex Gorsky Chairman/CEO | 1.50M | — | 9.47M | 4.17M | 5.02M | 4.84M | 24.99M | 54.57% | ↗ |
| 85 | 2014 | Alex Gorsky Chairman, CEO | 1.50M | — | 9.47M | 4.17M | 5.02M | 4.84M | 24.99M | 54.57% | ↗ |
| 86 | 2014 | Paulus Stoffels EVP, CSO | 1.08M | — | 10.69M | 1.31M | 2.57M | 2.69M | 18.34M | 65.42% | ↗ |
| 87 | 2014 | Paulus Stoffels Chief Scientific Officer; Worldwide Chairman, Pharmaceuticals | 1.08M | — | 10.69M | 1.31M | 2.57M | 2.69M | 18.34M | 65.42% | ↗ |
| 88 | 2014 | Paulus Stoffels CSO; Worldwide Chairman, Pharmaceuticals | 1.08M | — | 10.69M | 1.31M | 2.57M | 2.69M | 18.34M | 65.42% | ↗ |
| 89 | 2014 | Dominic Caruso VP, Finance, CFO | 878.1K | — | 3.27M | 1.33M | 3.23M | 1.63M | 10.35M | 44.49% | ↗ |
| 90 | 2014 | Dominic Caruso EVP, CFO | 878.1K | — | 3.27M | 1.33M | 3.23M | 1.63M | 10.35M | 44.49% | ↗ |
| 91 | 2014 | Sandra Peterson EVP, Group Worldwide Chairman | 841.3K | — | 2.83M | 1.37M | 1.40M | 643.7K | 7.09M | 59.29% | ↗ |
| 92 | 2014 | Sandra Peterson Group Worldwide Chairman | 841.3K | — | 2.83M | 1.37M | 1.40M | 643.7K | 7.09M | 59.29% | ↗ |
| 93 | 2014 | Michael Ullmann VP, General Counsel | 591.3K | — | 1.62M | 721.9K | 1.50M | 1.53M | 5.96M | 39.21% | ↗ |
| 94 | 2013 | Alex Gorsky Chairman/CEO | 1.45M | — | 5.99M | 2.67M | 4.87M | 1.93M | 16.91M | 51.20% | ↗ |
| 95 | 2013 | Dominic Caruso VP, Finance, CFO | 842.3K | — | 2.66M | 1.14M | 3.22M | 364.9K | 8.23M | 46.19% | ↗ |
| 96 | 2013 | Paulus Stoffels Chief Scientific Officer; Worldwide Chair, Pharmaceuticals | 952.9K | — | 2.58M | 1.11M | 2.42M | 761.8K | 7.82M | 47.18% | ↗ |
| 97 | 2013 | Paulus Stoffels Chief Scientific Officer; Worldwide Chairman, Pharmaceuticals | 952.9K | — | 2.58M | 1.11M | 2.42M | 761.8K | 7.82M | 47.18% | ↗ |
| 98 | 2013 | Paulus Stoffels CSO; Worldwide Chairman, Pharmaceuticals | 952.9K | — | 2.58M | 1.11M | 2.42M | 761.8K | 7.82M | 47.18% | ↗ |
| 99 | 2013 | Sandra Peterson Group Worldwide Chairman | 800.0K | 1.90M | 635.9K | 300.0K | 1.20M | 801.4K | 5.64M | 16.60% | ↗ |
| 100 | 2013 | Sandra Peterson Group Worldwide Chair | 800.0K | 1.90M | 635.9K | 300.0K | 1.20M | 801.4K | 5.64M | 16.60% | ↗ |
| 101 | 2013 | Michael Ullmann VP, General Counsel | 542.3K | — | 1.39M | 656.2K | 1.35M | 424.8K | 4.36M | 46.92% | ↗ |
| 102 | 2012 | William Weldon Former Chairman/CEO | 1.32M | — | 7.57M | 4.02M | 13.45M | 3.48M | 29.84M | 38.83% | ↗ |
| 103 | 2012 | Alex Gorsky Chairman/CEO | 1.09M | — | 2.79M | 1.48M | 3.41M | 2.21M | 10.98M | 38.93% | ↗ |
| 104 | 2012 | Dominic Caruso VP, Finance; CFO | 796.4K | — | 2.09M | 1.11M | 3.01M | 999.0K | 8.01M | 39.95% | ↗ |
| 105 | 2012 | Dominic Caruso VP, Finance, CFO | 796.4K | — | 2.09M | 1.11M | 3.01M | 999.0K | 8.01M | 39.95% | ↗ |
| 106 | 2012 | Paulus Stoffels CSO; Worldwide Chairman, Pharmaceuticals | 825.4K | — | 1.93M | 1.02M | 2.31M | 1.26M | 7.34M | 40.21% | ↗ |
| 107 | 2012 | Paulus Stoffels Chief Scientific Officer; Worldwide Chair, Pharmaceuticals | 825.4K | — | 1.93M | 1.02M | 2.31M | 1.26M | 7.34M | 40.21% | ↗ |
| 108 | 2012 | Sandra Peterson Group Worldwide Chairman | 46.2K | 300.0K | 4.30M | — | — | 52.7K | 4.70M | 91.51% | ↗ |
| 109 | 2012 | Sandra Peterson Group Worldwide Chair | 46.2K | 300.0K | 4.30M | — | — | 52.7K | 4.70M | 91.51% | ↗ |
| 110 | 2012 | Peter Fasolo VP, Global Human Resources | 534.8K | — | 1.39M | 737.0K | 715.2K | 247.2K | 3.62M | 58.66% | ↗ |
| 111 | 2011 | William Weldon Former Chairman/CEO | 1.91M | — | 2.61M | 4.19M | 14.34M | 3.76M | 26.80M | 25.37% | ↗ |
| 112 | 2011 | William C. Weldon Chairman/CEO | 1.91M | — | 2.61M | 4.19M | 14.34M | 3.76M | 26.80M | 25.37% | ↗ |
| 113 | 2011 | Russell C. Deyo VP, General Counsel | 895.3K | — | 783.7K | 1.26M | 3.97M | 2.07M | 8.98M | 22.76% | ↗ |
| 114 | 2011 | Sherilyn S. McCoy Vice Chairman, Executive Committee | 897.8K | — | 705.4K | 1.13M | 3.92M | 2.07M | 8.73M | 21.05% | ↗ |
| 115 | 2011 | Alex Gorsky Vice Chairman, Executive Committee | 847.7K | — | 673.2K | 1.08M | 2.84M | 1.40M | 6.84M | 25.66% | ↗ |
| 116 | 2011 | Alex Gorsky Chairman/CEO | 847.7K | — | 673.2K | 1.08M | 2.84M | 1.40M | 6.84M | 25.66% | ↗ |
| 117 | 2011 | Dominic Caruso VP, Finance, CFO | 773.0K | — | 676.7K | 1.09M | 2.97M | 934.7K | 6.44M | 27.37% | ↗ |
| 118 | 2011 | Dominic Caruso VP, Finance; CFO | 773.0K | — | 676.7K | 1.09M | 2.97M | 934.7K | 6.44M | 27.37% | ↗ |
| 119 | 2011 | Dominic J. Caruso VP, Finance; CFO | 773.0K | — | 676.7K | 1.09M | 2.97M | 934.7K | 6.44M | 27.37% | ↗ |
| 120 | 2010 | William Weldon Former Chairman/CEO | 1.85M | — | 2.77M | 4.71M | 12.04M | 7.34M | 28.72M | 26.07% | ↗ |
| 121 | 2010 | William C. Weldon Chairman/CEO | 1.85M | — | 2.77M | 4.71M | 12.04M | 7.34M | 28.72M | 26.07% | ↗ |
| 122 | 2010 | Russell C. Deyo VP, General Counsel | 867.4K | — | 622.7K | 1.06M | 3.83M | 2.47M | 8.85M | 18.99% | ↗ |
| 123 | 2010 | Colleen A. Goggins WW Chairman, Consumer Group | 823.0K | — | 634.1K | 1.08M | 3.40M | 1.80M | 7.74M | 22.12% | ↗ |
| 124 | 2010 | Sherilyn S. McCoy Vice Chairman, Executive Committee | 780.4K | — | 679.3K | 1.15M | 3.22M | 1.68M | 7.52M | 24.39% | ↗ |
| 125 | 2010 | Dominic J. Caruso VP, Finance; CFO | 749.9K | — | 566.1K | 961.9K | 2.55M | 804.1K | 5.63M | 27.13% | ↗ |
| 126 | 2010 | Dominic Caruso VP, Finance; CFO | 749.9K | — | 566.1K | 961.9K | 2.55M | 804.1K | 5.63M | 27.13% | ↗ |
| 127 | 2009 | William C. Weldon Chairman/CEO | 1.80M | — | 2.76M | 5.24M | 12.83M | 8.18M | 30.81M | 25.96% | ↗ |
| 128 | 2009 | Russell C. Deyo VP, General Counsel | 831.8K | — | 611.4K | 1.16M | 3.61M | 2.42M | 8.63M | 20.51% | ↗ |
| 129 | 2009 | Russell C. Deyo VP, HR & General Counsel | 831.8K | — | 611.4K | 1.16M | 3.61M | 2.42M | 8.63M | 20.51% | ↗ |
| 130 | 2009 | Colleen A. Goggins WW Chairman, Consumer Group | 795.9K | — | 634.0K | 1.20M | 3.78M | 1.90M | 8.32M | 22.08% | ↗ |
| 131 | 2009 | Sherilyn S. McCoy WW Chairman, Pharmaceuticals Group | 747.7K | — | 407.6K | 772.8K | 2.63M | 1.23M | 5.78M | 20.42% | ↗ |
| 132 | 2009 | Sherilyn S. McCoy Vice Chairman, Executive Committee | 747.7K | — | 407.6K | 772.8K | 2.63M | 1.23M | 5.78M | 20.42% | ↗ |
| 133 | 2009 | Dominic J. Caruso VP, Finance, CFO | 723.7K | — | 486.8K | 923.1K | 2.44M | 645.4K | 5.22M | 27.01% | ↗ |
| 134 | 2009 | Dominic J. Caruso VP, Finance; CFO | 723.7K | — | 486.8K | 923.1K | 2.44M | 645.4K | 5.22M | 27.01% | ↗ |
| 135 | 2008 | William C. Weldon Chairman/CEO | 1.79M | — | 2.45M | 3.98M | 12.60M | 8.31M | 29.13M | 22.08% | ↗ |
| 136 | 2008 | Christine A. Poon Vice Chairman WW Chairman, Pharmaceuticals Group | 1.04M | — | 912.4K | 2.17M | 3.72M | 2.55M | 10.40M | 29.65% | ↗ |
| 137 | 2008 | Russell C. Deyo VP, HR & General Counsel | 804.1K | — | 618.7K | 1.00M | 3.51M | 2.04M | 7.98M | 20.33% | ↗ |
| 138 | 2008 | Russell C. Deyo VP, General Counsel | 804.1K | — | 618.7K | 1.00M | 3.51M | 2.04M | 7.98M | 20.33% | ↗ |
| 139 | 2008 | Colleen A. Goggins WW Chairman, Consumer Group | 766.6K | — | 630.2K | 1.02M | 3.69M | 1.67M | 7.78M | 21.25% | ↗ |
| 140 | 2008 | Dominic J. Caruso VP, Finance, CFO | 701.4K | — | 389.6K | 632.2K | 2.00M | 496.4K | 4.22M | 24.22% | ↗ |
| 141 | 2008 | Dominic J. Caruso VP, Finance; CFO | 701.4K | — | 389.6K | 632.2K | 2.00M | 496.4K | 4.22M | 24.22% | ↗ |
| 142 | 2007 | William C. Weldon Chairman/CEO | 1.73M | — | 2.32M | 5.34M | 12.14M | 6.89M | 28.40M | 26.96% | ↗ |
| 143 | 2007 | Christine A. Poon Vice Chairman | 1.01M | — | 613.7K | 2.56M | 3.72M | 2.64M | 10.54M | 30.08% | ↗ |
| 144 | 2007 | Christine A. Poon Vice Chairman WW Chairman, Pharmaceuticals Group | 1.01M | — | 613.7K | 2.56M | 3.72M | 2.25M | 10.14M | 31.27% | ↗ |
| 145 | 2007 | Russell C. Deyo VP, General Counsel | 769.6K | — | 579.9K | 2.02M | 2.75M | 2.95M | 9.06M | 28.69% | ↗ |
| 146 | 2007 | Russell C. Deyo VP, HR & General Counsel | 769.6K | — | 579.9K | 1.33M | 3.95M | 1.75M | 8.38M | 22.85% | ↗ |
| 147 | 2007 | Colleen A. Goggins WW Chairman, Consumer Group | 729.9K | — | 579.9K | 1.33M | 3.88M | 1.33M | 7.86M | 24.36% | ↗ |
| 148 | 2007 | Dominic J. Caruso VP, Finance, CFO | 550.0K | — | 208.8K | 480.5K | 1.55M | 352.0K | 3.14M | 21.94% | ↗ |
| 149 | 2006 | William C. Weldon Chairman/CEO | 1.66M | — | 2.04M | 9.24M | 7.46M | 9.18M | 29.58M | 38.13% | ↗ |
| 150 | 2006 | Robert J. Darretta Vice Chairman/CFO | 1.02M | — | 626.2K | 3.23M | 2.57M | 3.81M | 11.26M | 34.23% | ↗ |
| 151 | 2006 | Russell C. Deyo VP, General Counsel | 735.4K | — | 510.2K | 2.55M | 2.21M | 2.90M | 8.91M | 34.36% | ↗ |
| 152 | 2006 | Per A. Peterson Chairman, R&D Pharmaceuticals Group | 830.7K | — | 579.8K | 3.05M | 2.31M | 1.92M | 8.70M | 41.75% | ↗ |
| 153 | 2006 | Russell C. Deyo VP, General Counsel/Chief Compliance Officer | 735.4K | — | 510.2K | 2.55M | 2.21M | 2.38M | 8.39M | 36.49% | ↗ |
| 154 | 2006 | Christine A. Poon Vice Chairman WW Chairman, Pharmaceuticals Group | 967.3K | — | 270.6K | 2.50M | 2.39M | 2.04M | 8.17M | 33.97% | ↗ |
| 155 | 2006 | Christine A. Poon Vice Chairman | 967.3K | — | 270.6K | 2.50M | 2.39M | 1.75M | 7.88M | 35.21% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joaquin Duato | Chief Executive Officer & Chairman | 6M | male |
| Jennifer L. Taubert | Executive Vice President & Worldwide Chairman of Innovative Medicine | 3M | female |
| Joseph J. Wolk | Executive Vice President & Chief Financial Officer | 3M | male |
| John C. Reed | Executive Vice President of Innovative Medicine and R&D | 3M | — |
| Timothy Schmid | Executive Vice President & Worldwide Chairman of MedTech | 3M | male |
| Kristen Blair Mulholland | Executive Vice President & Chief Human Resources Officer | 2M | female |
| Guy J. Lebeau | Group Chairman of MD&D Business - EMEA | — | — |
| Elizabeth Forminard | Executive Vice President & Chief Legal Officer | — | female |
| James Swanson | Executive Vice President & Chief Information Officer | — | male |
| Robert J. Decker Jr. | Controller & Chief Accounting Officer | — | male |
| Darren Snellgrove | Vice President of Investor Relations | — | male |
| Dirk Brinckman | Chief Compliance Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - GENERAL
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-19 | 2026-04-14 | John Boozman | AR | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2024-10-29 | 2024-11-15 | Tommy Tuberville | AL | Joint | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2024-07-03 | 2024-08-21 | Sheldon Whitehouse | RI | Spouse | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2023-12-14 | 2024-01-17 | Jerry Moran | KS | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-10-16 | 2023-11-16 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-09-21 | 2023-10-20 | Pete Ricketts | NE | Spouse | Sale (Full) | $100,001 - $250,000 | ↗ |
| 2023-08-22 | 2023-09-22 | Dan Sullivan | AK | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2022-10-17 | 2022-11-13 | Shelley Moore Capito | WV | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2022-01-18 | 2022-02-03 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2021-09-30 | 2021-10-15 | Tommy Tuberville | AL | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2021-03-29 | 2021-07-23 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-08-21 | 2020-09-08 | Jerry Moran | KS | Self | Purchase | $1,001 - $15,000 | ↗ |
| 2020-04-16 | 2021-05-02 | David Perdue | — | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-04-14 | 2020-05-08 | David Perdue | — | Joint | Sale (Full) | $50,001 - $100,000 | ↗ |
| 2020-03-09 | 2020-03-27 | Bill Cassidy | LA | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2020-03-03 | 2020-04-29 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2019-09-25 | 2019-10-21 | Jerry Moran | KS | Self | Purchase | $1,001 - $15,000 | ↗ |
| 2018-10-24 | 2018-11-08 | David Perdue | — | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2018-10-17 | 2018-11-08 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2018-04-24 | 2018-05-14 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-13 | 2026-05-13 | Ro Khanna | CA17 | Spouse | Purchase | $15,001 - $50,000 | ↗ |
| 2026-03-26 | 2026-04-14 | Thomas H. Kean | NJ07 | — | Sale | $1,001 - $15,000 | ↗ |
| 2026-03-19 | 2026-04-07 | Richard Dean Dr McCormick | GA06 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2026-03-10 | 2026-04-08 | Lloyd Doggett | TX37 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2026-03-06 | 2026-04-09 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2026-03-06 | 2026-04-09 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2026-01-23 | 2026-02-20 | Thomas H. Kean | NJ07 | — | Sale | $15,001 - $50,000 | ↗ |
| 2025-12-18 | 2026-01-16 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-12-09 | 2026-01-05 | Lloyd Doggett | TX37 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-11-20 | 2025-12-19 | Thomas H. Kean | NJ07 | — | Sale | $15,001 - $50,000 | ↗ |
| 2025-11-13 | 2025-12-12 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-11-05 | 2025-12-10 | Rich McCormick | — | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-10-30 | 2025-11-14 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-10-10 | 2025-11-24 | Jared Moskowitz | FL23 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-09-29 | 2025-10-03 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-09-23 | 2025-10-10 | Valerie Hoyle | OR04 | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-08-19 | 2025-09-12 | Kelly Louise Morrison | MN03 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-08-14 | 2025-09-12 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-08-04 | 2025-09-12 | Ro Khanna | CA17 | Spouse | Purchase | $1,000 - $15,000 | ↗ |
| 2025-08-04 | 2025-09-15 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JNJ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
